Medprin Regenerative Medical Technologies Future Growth
Future criteria checks 5/6
Medprin Regenerative Medical Technologies is forecast to grow earnings and revenue by 28.5% and 25.8% per annum respectively. EPS is expected to grow by 28.3% per annum. Return on equity is forecast to be 14.9% in 3 years.
Key information
28.5%
Earnings growth rate
28.3%
EPS growth rate
| Medical Equipment earnings growth | 26.5% |
| Revenue growth rate | 25.8% |
| Future return on equity | 14.9% |
| Analyst coverage | Low |
| Last updated | 23 Aug 2024 |
Recent future growth updates
No updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 490 | 122 | N/A | 105 | 1 |
| 12/31/2025 | 382 | 106 | N/A | 93 | 1 |
| 12/31/2024 | 301 | 68 | N/A | 114 | 1 |
| 9/30/2024 | 276 | 68 | 65 | 100 | N/A |
| 6/30/2024 | 267 | 61 | 59 | 105 | N/A |
| 3/31/2024 | 244 | 48 | 60 | 104 | N/A |
| 12/31/2023 | 231 | 41 | 68 | 108 | N/A |
| 9/30/2023 | 202 | 31 | 20 | 89 | N/A |
| 6/30/2023 | 186 | 27 | -8 | 67 | N/A |
| 3/31/2023 | 202 | 37 | -30 | 70 | N/A |
| 1/1/2023 | 195 | 36 | -88 | 48 | N/A |
| 9/30/2022 | 190 | 43 | -80 | 66 | N/A |
| 6/30/2022 | 180 | 45 | -105 | 64 | N/A |
| 3/31/2022 | 159 | 41 | -103 | 58 | N/A |
| 1/1/2022 | 154 | 45 | -86 | 67 | N/A |
| 9/30/2021 | 145 | 46 | -76 | 56 | N/A |
| 6/30/2021 | 140 | 42 | -47 | 48 | N/A |
| 3/31/2021 | 137 | 43 | -38 | 46 | N/A |
| 12/31/2020 | 124 | 37 | -28 | 34 | N/A |
| 12/31/2019 | 113 | 28 | -5 | 31 | N/A |
| 12/31/2018 | 86 | -19 | -14 | 6 | N/A |
| 12/31/2017 | 54 | -19 | N/A | 6 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 301033's forecast earnings growth (28.5% per year) is above the savings rate (2.8%).
Earnings vs Market: 301033's earnings (28.5% per year) are forecast to grow faster than the CN market (26.1% per year).
High Growth Earnings: 301033's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 301033's revenue (25.8% per year) is forecast to grow faster than the CN market (13.8% per year).
High Growth Revenue: 301033's revenue (25.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 301033's Return on Equity is forecast to be low in 3 years time (14.9%).